458 related articles for article (PubMed ID: 27645342)
1. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
4. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.
Grebenciucova E; Reder AT; Bernard JT
Mult Scler Relat Disord; 2016 Sep; 9():158-62. PubMed ID: 27645366
[TBL] [Abstract][Full Text] [Related]
5. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
[No Abstract] [Full Text] [Related]
6. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
7. Cryptococcal meningoencephalitis in an IgG
Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
[TBL] [Abstract][Full Text] [Related]
8. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
9. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Walker S; Brew B
J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
[TBL] [Abstract][Full Text] [Related]
10. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
[No Abstract] [Full Text] [Related]
11. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Sharim J; Tashjian R; Golzy N; Pouratian N
J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod.
Pham C; Bennett I; Jithoo R
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28687690
[TBL] [Abstract][Full Text] [Related]
13. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
[No Abstract] [Full Text] [Related]
14. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
Thomas K; Proschmann U; Ziemssen T
Expert Opin Pharmacother; 2017 Oct; 18(15):1649-1660. PubMed ID: 28844164
[TBL] [Abstract][Full Text] [Related]
18. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
[No Abstract] [Full Text] [Related]
19. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
[TBL] [Abstract][Full Text] [Related]
20. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
Datt J; Baldock L; Pull E; Webber B
Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
